Grant of options

Fusion Antibodies PLC

20 July 2026

 

20 July 2026

Fusion Antibodies plc

("Fusion" or the "Company")

Grant of options

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Company has granted 2,910,000 options (the "Options") over ordinary shares of 4 pence each in the Company ("Ordinary Shares") to certain Executive Directors and employees of the Company. The Options were granted pursuant to the Fusion Antibodies EMI and Unapproved Employee Share Option Scheme (the "Scheme"), adopted by the Company on 11 December 2017.

The Options have an exercise price of 10.30 pence per Option, being the closing mid-market price of an Ordinary Share on 17 July 2026, the business day prior to the date of grant. The Options will vest equally over a three-year period, with one third of the Options vesting on each anniversary following the grant date and subject to continuing employment only.  Once vested, the Options can be exercised for a period of ten years from the grant date.

1,000,000 of the Options have been granted to the following Executive Directors of the Company:

Name	Number of Options granted	Existing options over Ordinary Shares held	Total Options over Ordinary Shares held following grant
Adrian Kinkaid, CEO	600,000	900,000	1,500,000
Richard Buick, CSO	400,000	680,000	1,080,000

Following the grant of the Options, the Company has options in issue over a total of 6,086,600 Ordinary Shares, representing 4.86 per cent. of the Company's issued share capital.

The table at the end of this announcement, which is provided in accordance with the requirements of the UK Market Abuse Regulation, provides further details.

Enquiries: 

Fusion Antibodies plc	www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer	Via Walbrook PR
Allenby Capital Limited	Tel: [phone]
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)	Tel: [phone]
Walbrook PR	Tel: [phone] or [e-mail]
Anna Dunphy	Mob: [phone]

Investor Hub                                                                                                      

We encourage all investors to share questions on this announcement via our investor hub https://investorhub.fusionantibodies.com/link/rJaa9e

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx ^TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and/or expressed over 750 antibodies and successfully completed over 250 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Name Position Adrian Kinkaid Director - Chief Executive Officer Richard Buick Director - Chief Scientific Officer
2	Reason for the notification
a)	Position/status	See 1(a)
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Fusion Antibodies plc
b)	LEI	213800KBAYRC9VOQ9V39
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares of 4p each in Fusion Antibodies plc Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16
b)	Nature of the transaction	Grant of options over ordinary shares
c)	Price(s) and volume(s)	Name  Price(s) Volume(s) Adrian Kinkaid 10.30p 600,000 Richard Buick 10.30p 400,000
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	20 July 2026
f)	Place of the transaction	Outside a trading venue

 

END